PHATHOM PHARMACEUTICALS, INC. (PHAT) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 121.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $121.95M | (m) |
| 2026-03-31 | (m) | $63.73M | (m) |
| 2025-12-31 | (m) | $-221.25M | (m) |
| 2025-09-30 | (m) | $-274.55M | (m) |
| 2025-06-30 | (m) | $-330.15M | (m) |
| 2025-03-31 | (m) | $-345.79M | (m) |
| 2024-12-31 | (m) | $-334.33M | (m) |
| 2024-09-30 | (m) | $-339.44M | (m) |
| 2024-06-30 | (m) | $-297.11M | (m) |
| 2024-03-31 | (m) | $-246.63M | (m) |
| 2023-12-31 | (m) | $-201.59M | (m) |
| 2023-09-30 | (m) | $-177.07M | (m) |
| 2023-06-30 | (m) | $-184.92M | (m) |
| 2023-03-31 | (m) | $-194.87M | (m) |
| 2022-12-31 | (m) | $-197.72M | (m) |
| 2022-09-30 | (m) | $-178.50M | (m) |
| 2022-06-30 | (m) | $-164.07M | (m) |
| 2022-03-31 | (m) | $-149.71M | (m) |
| 2021-12-31 | (m) | $-143.88M | (m) |
| 2021-09-30 | (m) | $-161.78M | (m) |
| 2021-06-30 | (m) | $-159.22M | (m) |
| 2021-03-31 | (m) | $-143.77M | (m) |
| 2020-12-31 | (m) | $-129.07M | (m) |
| 2020-09-30 | (m) | $-173.35M | (m) |
| 2020-06-30 | (m) | $-207.36M | (m) |
| 2020-03-31 | (m) | $-274.02M | (m) |
| 2019-12-31 | (m) | $-255.13M | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
| 2018-12-31 | (m) | $-1.29M | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |